GRACELL BIOTECHNOLOGIES-ADR (GRCL) Earnings History & Surprises
NASDAQ:GRCL • US38406L1035
10.25 USD
+0.01 (+0.05%)
At close: Feb 21, 2024
10.25 USD
0 (0%)
After Hours: 2/21/2024, 8:00:01 PM
Past quarterly earnings results for GRACELL BIOTECHNOLOGIES-ADR (GRCL), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Release DateMar 11, 2024
PeriodQ4 / 2023
EPS Estimate-CN¥0.14
Revenue Estimate
Last Reported
Release DateNov 13, 2023
PeriodQ3 / 2023
EPS Reported-CN¥0.10
EPS Surprise 50.15%
Revenue Surprise %
Beat Rate
19%
EPS and Revenuebeats vs estimates
Quarterly Earnings Results
EPS & Revenue History (CNY)
Actual vs estimated values, surprises, q2q growth and acceleration numbers for recent quarters.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2023 | -0.10 | -0.20 | 50.15% | 71.43% | - | - | ||
| Q2 2023 | -0.30 | -0.41 | 26.47% | - | - | - | ||
| Q1 2023 | -0.35 | -0.40 | 13.13% | - | - | - | ||
| Q4 2022 | -0.30 | -0.21 | -42.78% | - | - | - | ||
| Q3 2022 | -0.35 | -0.15 | -136.32% | -16.67% | 25.5K | -100.00% | -100.00% | |
| Q2 2022 | -0.30 | -0.08 | -283.62% | -50.00% | - | - | ||
| Q1 2022 | -0.35 | -0.21 | -63.40% | -40.00% | - | - | ||
| Q4 2021 | -0.30 | -0.34 | 10.87% | -87.50% | - | - | ||
| Q3 2021 | -0.30 | -0.12 | -145.10% | - | 370K | - | - | |
| Q2 2021 | -0.20 | -0.12 | -68.06% | - | - | - | ||
| Q1 2021 | -0.25 | -0.22 | -14.89% | - | - | - | ||
| Q4 2020 | -0.16 | -0.26 | 38.73% | - | - | - | ||
| Q3 2020 | - | - | - | - | ||||
| Q2 2020 | - | - | - | - | ||||
| Q1 2020 | - | - | - | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
2
Average EPS beat (4)
-34.87%
Max EPS beat (4)
26.47%
Min EPS beat (4)
-136.32%
Revenue beat statistics
Revenue beat (4)
N/A
Average Revenue beat (4)
N/A
Max Revenue beat (4)
N/A
Min Revenue beat (4)
N/A
Analysis
In the last 4 quarters, GRCL has beaten EPS estimates in 2 out of 4 releases
In the last 4 quarters, GRCL reported -34.9% below the EPS estimates on average.
GRACELL BIOTECHNOLOGIES-ADR / GRCL Earnings FAQ
When did GRACELL BIOTECHNOLOGIES-ADR (GRCL) report earnings last quarter?
GRACELL BIOTECHNOLOGIES-ADR (GRCL) last reported earnings on 11/13/2023.
Did GRCL stock beat earnings estimates in the most recent quarter?
GRACELL BIOTECHNOLOGIES-ADR (GRCL) beat EPS estimates and missed revenue estimates in the most recent quarter.
What percentage of the time does GRCL stock beat earnings estimates?
In the last 4 quarters, GRACELL BIOTECHNOLOGIES-ADR (GRCL) has beaten EPS estimates in 2 out of 4 releases.